Summary

Laser Microdissection-Based Protocol for the LC-MS/MS Analysis of the Proteomic Profile of Neuromelanin Granules

Published: December 16, 2021
doi:

Summary

A robust protocol is presented here for isolating neuromelanin granules from human post-mortem substantia nigra pars compacta tissue via laser microdissection. This revised and optimized protocol massively minimizes the required time for sample collection, reduces the required sample amount, and enhances the identification and quantification of proteins by LC-MS/MS analysis.

Abstract

Neuromelanin is a black-brownish pigment, present in so-called neuromelanin granules (NMGs) in dopaminergic neurons of the substantia nigra pars compacta. Besides neuromelanin, NMGs contain a variety of proteins, lipids, and metals. Although NMGs-containing dopaminergic neurons are preferentially lost in neurodegenerative diseases like Parkinson's disease and dementia with Lewy bodies, only little is known about the mechanism of NMG formation and the role of NMGs in health and disease. Thus, further research on the molecular characterization of NMGs is essential. Unfortunately, standard protocols for the isolation of proteins are based on density gradient ultracentrifugation and therefore require high amounts of human tissue. Thus, an automated laser microdissection (LMD)-based protocol is established here which allows the collection of NMGs and surrounding substantia nigra (SN) tissue using minimal amounts of tissue in an unbiased, automatized way. Excised samples are subsequently analyzed by mass spectrometry to decipher their proteomic composition. With this workflow, 2,079 proteins were identified of which 514 proteins were exclusively identified in NMGs and 181 in SN. The present results have been compared with a previous study using a similar LMD-based approach reaching an overlap of 87.6% for both proteomes, verifying the applicability of the revised and optimized protocol presented here. To validate current findings, proteins of interest were analyzed by targeted mass spectrometry, e.g., parallel reaction monitoring (PRM)-experiments.

Introduction

Every tissue consists of a heterogeneous mixture of different cell types, but the specific isolation of one cell type often is indispensable for a more precise characterization. Laser microdissection (LMD), coupling a microscope with a laser application, is a powerful tool for the specific isolation of tissue areas, single cells, or cellular substructures out of a complex composite. The application of LMD in combination with mass spectrometry (LMD-MS) has already been successfully implemented for several research questions, including isolation of DNA1, RNA2 and proteins3,4,5. In this protocol, a revised and optimized LMD-MS protocol is described for the proteomic analysis of human post-mortem brain tissue and sub-cellular components to decipher novel pathomechanisms of Parkinson's disease.

Neuromelanin is a black, nearly-insoluble pigment found in the catecholaminergic, dopamine-producing neurons of the substantia nigra pars compacta6. Together with proteins and lipids, it accumulates in organelle-like granules surrounded by a double membrane, called neuromelanin granules (NMGs)7,8,9. NMGs can be observed from the age of three years in humans increasing in quantity and density during the aging process10,11. To date, there is no definite hypothesis on neuromelanin formation, but one assumption is that neuromelanin is formed through the oxidation of dopamine12. Other hypotheses are based on enzymatic production of neuromelanin (e.g., tyrosinase)13. Neuromelanin itself was found to have a high binding affinity to lipids, toxins, metal ions, and pesticides. Based on these findings, the formation of NMGs is assumed to protect the cell from the accumulation of toxic and oxidative substances and from environmental toxins14,15. Besides this neuroprotective function, there is evidence that neuromelanin may cause neurodegenerative effects, e.g., by iron saturation and the subsequent catalysis of free radicals16,17. Furthermore, neuromelanin released during neurodegenerative processes can be decomposed by hydrogen peroxide, which could accelerate necrosis by reactive metals and other toxic compounds previously bound to neuromelanin and may contribute to neuroinflammation and cellular damage18. However, until now the exact role of NMGs in neurodegenerative processes like in the course of Parkinson's disease is not clearly understood. Still, NMGs seem to be involved in the pathogenesis of Parkinson's disease and their specific analysis is of utmost importance to unravel their role in neurodegeneration. Unfortunately, common laboratory animals (e.g., mice and rats) and cell lines lack NMGs19. Therefore, researchers especially rely on post-mortem brain tissue for their analysis. In the past, NMG isolation by density gradient centrifugation relied on the availability of high amounts of substantia nigra tissue20,21. Today, LMD presents a versatile tool to specifically isolate NMGs from human brain samples to then analyze them by LC-MS/MS.

In this protocol, an improved and automated version of a previous protocol22 is presented for the isolation of NMGs and surrounding tissue (SN), enabling a faster sample generation, higher numbers of identified and quantified proteins, and a severe reduction of required tissue amounts.

Protocol

The use of human brain tissue was approved by the ethics committee of the Ruhr-University Bochum, Germany (file number 4760-13), according to German regulations and guidelines. This protocol has been applied on commercially obtained substantia nigra pars compacta tissue slices. A graphical overview of the presented protocol is shown in Figure 1.

1. Tissue sectioning

  1. Precool the cryostat chamber.
    NOTE: Every tissue requires different cryostat temperatures, which can be found in the respective vendor protocol.
  2. Clean the stainless-steel knife with 70% ethanol and install it into the blade holder.
  3. Transfer the tissue from the -80 °C freezer to the cryostat using an icebox and let it adjust to the cryostat chamber temperature for 15 min.
  4. Unambiguously label membrane slides using a pencil.
    NOTE: PET/PEN membrane slides are required for the LMD-based sample collection. Handle the PET/PEN membrane slides with care as they are extremely fragile.
  5. Apply a drop of commercial frozen section medium on the tissue holder. Before it is completely frozen, place the tissue onto the frozen section medium and let it harden, so that the tissue is connected with the tissue holder.
  6. Install the tissue holder in the cryostat chamber and adjust its orientation before you start sectioning. Optimal holder orientation depends on the orientation of the tissue.
    NOTE: It may be necessary to trim the tissue until the section plane needed for the slices is reached.
  7. Before the tissue area of interest is reached, adjust the cutting setting to the desired tissue thickness.
    NOTE: 5 or 10 µm is the suggested thickness for this protocol as 20 µm thick sections were found to be incompatible with the LMD-based sample collection22.
  8. Cut two sections and discard them.
  9. Put down the Anti-roll Plate.
  10. Cut a section of the tissue, open the Anti-roll Plate carefully, take a membrane slide, and prevent tissue folding while placing the tissue section on the membrane slide.
    NOTE: Storing the membrane slides at room temperature prior to adhesion enables accurate sample attachment. Several sections may be placed on the same membrane slide but tissue overlapping must be prevented.
  11. Store tissue sections placed on membrane slides in the cryostat until sectioning is completed.
  12. Store the cryosected tissue at -20 °C until further processing or directly proceed with the procedure below. Store the sectioned tissue slides at -80 °C until further use.

2. Laser Microdissection and Pressure Catapulting

NOTE: As neuromelanin granules are visible without any staining due to their black-brownish color, no staining is necessary for this protocol. Nevertheless, different staining procedures can be combined with this protocol if required. Keep in mind that the use of blocking solutions or antibodies will influence the LC-MS/MS analyses.

  1. Switch on the MicroBeam system and open the associated software on the computer (see Table of Materials).
  2. Place the tissue membrane slide in the SlideHolder on the RoboStage with the tissue facing upwards.
    NOTE: Depending on the LMD device, it may be necessary to place the membrane slide such that the tissue is facing down. In general, sample collection is performed in a temperature-controlled environment to ensure optimal and reproducible conditions.
  3. Set the microscope to the desired magnification (50-fold is used here) for the overview scans.
  4. Use the Scan function, which can be found in the Navigator window of the software interface, to acquire an overview scan of the tissue section. Search for the top-left corner and the bottom-right corner of the area of interest and select them in the software interface. Then, select Scan all ROIs to perform the scans.
    NOTE: Overview scans are not mandatory, but they enable better orientation in the slide and can be saved for later usage.
  5. Adjust the magnification of the microscope for the appropriate tissue, which is 400-fold in the present case of neuromelanin granules.
  6. Search for an area with neuromelanin granules. Select Field of View Analysis in the software interface, select Invert Result, and set the threshold for the RGB channels so that only neuromelanin granules are highlighted in red in the preview window. Click on OK to use the adjusted settings for the field of view.
    NOTE: It may occur that smaller objects having a dark color also get selected. To account for that, discard all objects covering an area smaller than 100 µm2 before isolating neuromelanin granules. To do this, open the Element List by clicking on the icon in the toolbar, select the slide under consideration and order elements by area. Select those with areas smaller than 100 µm2 and delete them.
  7. Adjust laser settings using an area of the slide that is covered by the membrane only.
    NOTE: It is suggested to use the Cut Laser Adjustment Wizard and follow the instructions of the software. Required laser settings may differ between different slides. For 5 µm sections with 400-fold magnification, typical settings are 32 energy and 51 focus for cutting, and 28 energy and -1 focus for laser pulse catapulting (LPC).
  8. Adjust speed settings for positioning and cutting to ensure proper isolation.
    NOTE: 30% speed was found to be optimal for NMG isolation.
  9. Fill the sample collection tube cap with 50 µL ultrapure water and insert the cap into the collector of the RoboMover.
    NOTE: The tube collector used for present experiments can carry one sample collection tube at a time.
  10. Position the RoboMover above the RoboStage II using the software interface to start sample collection.
    NOTE: To do this, open the RoboMover window, which displays the collector. Click on the sample collection tube cap displayed in the RoboMover window to move the cap to the working area. Adjust the optimal moving and working height in the RoboMover window. Otherwise, the water in the cap may drop onto the slide or the catapulted objects will not reach the cap.
  11. Start the laser. Control energy and focus settings during the laser process and adjust the settings if necessary. Ensure proper isolation and catapulting of the isolated objects into the sample collection tube cap for at least the first ten objects.
    NOTE: Proper isolation and catapulting have to be checked visually. Both should result in a tissue-free area of the size of the pre-selected object in the tissue slice (see Figure 2C,D). Adjust the laser settings if the object stays attached to the tissue slice after cutting and catapulting. For catapulting, the CenterRoboLPC option is found to be well suited for NMG isolation. The catapulting settings can be adjusted for each selected object in the Element List.
  12. When sampling is completed, navigate the RoboMover to its starting position. Remove the sample collection tube.
    NOTE: When the number of collected objects is rather low and objects are big enough, sample collection can be ensured by clicking on Cap Check, which will place the sample collection tube cap under the microscope so that the number of objects inside of the water in the cap can be counted (see Figure 2H).
  13. Spin down the sample using a centrifuge. Short spins of 5 s with increasing centrifugal force due to acceleration of the centrifuge were found to be sufficient. At this point, store samples at -80 °C, as all samples should be further processed together.
    NOTE: For the comparison of the proteomic profile, the tissue surrounding the NMGs was also isolated after their excision. The isolation of the surrounding tissue was performed at 50-fold magnification.
  14. Dry the samples in a vacuum concentrator. 1.5 h were found to be sufficient for 50 µL of water.
  15. Solubilize and lyse the tissue in 40 µL formic acid for 20 min (room temperature).
  16. Enhance tissue lysis by sonication at 45 kHz (kilohertz) for 5 min in a sonication bath. Fill the sonication bath with ice to prevent tubes from melting. Store the samples at -80 °C until further processing.

3. Tryptic digestion

  1. Defreeze samples on ice.
  2. Completely dry the samples in a vacuum concentrator.
  3. Fill up the sample with 50 µL of a suitable digestion buffer, e.g., 50 mM ammonium bicarbonate.
  4. After the addition of 1.25 µL of 200 mM 1,4-dithiothreitol, incubate the samples for 30 min at 60 °C and 300 rpm using a thermomixer and cool them down to room temperature (RT) afterwards.
  5. Then, incubate samples at RT for 30 min in the dark after the addition of 1.36 µL 0.55 M iodoacetamide.
  6. Add a suitable amount of trypsin to the samples and incubate the samples overnight (~16 h) at 37 °C.
    NOTE: For 1,000,000 µm2, 0.1 µg of trypsin was found to be sufficient.
  7. Add 2.6 µL of 10% trifluoroacetic acid (TFA) to the samples to stop the digestion (end concentration of 0.5% TFA).
  8. Completely dry the samples using a vacuum concentrator. Then, fill samples up to a defined final volume with 0.1% TFA. NMG samples were filled up to 20 µL of which 5 µL were used for one mass spectrometric (MS) experiment.
  9. Store the samples at -80 °C until further usage. Determine peptide concentration by amino acid analysis or another suitable quantification method (e.g., Direct Detect).
    ​NOTE: Low sample amounts may not be quantifiable using the mentioned techniques. To ensure identical sample loading, each sample should contain the same amount of isolated tissue and every sample should be treated equally.

4. High-performance liquid chromatography and mass spectrometry

NOTE: The following high-performance liquid chromatography (HPLC) mass spectrometric (MS) analysis are optimized for the specific LC system with a trapping column device and mass spectrometer used here (see Table of Materials). For other LC and MS systems, adaption of parameters is recommended.

  1. Using the software Xcalibur, adjust the HPLC settings as follows.
    1. Trap column: Set temperature to 60 °C, flow rate to 30 µL/min, running buffer to 0.1% trifluoroacetic acid.
    2. Analytical C18 reversed-phase column: Set temperature to 60 °C, flow rate to 30 µL/min, running buffer A to 0.1% trifluoroacetic acid, running buffer B to 84% acetonitrile, and gradient to 5%-30% running buffer B over 98 min.
      NOTE: Adaption of the gradient may be inevitable and is strongly recommended when using different tissues or cells. Total gradient time may vary due to sample loading at the beginning of the gradient and sample washing at the end of the gradient. The total gradient in this protocol consists of 7 min sample loading and additional column wash for 15 min resulting in a total gradient time of 120 min.
  2. Create a data-dependent acquisition (DDA) method using the XCalibur Instrument Setup, which can be found in the HPLC software roadmap menu.
  3. In the Global Parameters tab, define the infusion mode Liquid Chromatography, the Expected LC Peak Width (30 s), and the Default charge state (2).
  4. Proceed to the Scan Parameters tab and add the following scans and filters in the order mentioned: MS OT, MIPS, Intensity, Charge State, Dynamic exclusion, and ddMS2 OT HCD.
    NOTE: The detailed parameter settings for each scan and filter can be found in Supplementary Table 1. Optimal MS and DDA settings might vary for the specific mass spectrometer used as well as the sample type and should be, therefore, adapted.
  5. Prepare samples by dissolving 200-400 ng of sample peptides in a defined volume of 0.1% TFA in inert mass spectrometric glass vial inlets. If concentration determination is not applicable due to low sample amount, verify identical sample loading by comparing the Total Ion Current (TIC).
    NOTE: To do this, open the resulting file of mass spectrometric measurement in a suitable software, e.g., FreeStyle, and check the chromatogram. Intensities should be comparable for all samples. A representative TIC is shown in Figure 3.
  6. Analyze the raw data obtained using a proteomic suitable software, e.g., MaxQuant23, Progenesis QI for Proteomics, or Proteome Discoverer, and perform a statistical data analysis based on the research question.

5. Analysis of proteomic raw data using MaxQuant

NOTE: A detailed information on MaxQuant parameters is provided in Supplementary Table 2. They are briefly described below.

  1. Load raw files into the MaxQuant software in the raw data header by clicking Load.
  2. Assign sample names by clicking on Set Experiment.
  3. Define group-specific parameters. First, add modifications. Due to sample processing, choose Deamidation (NQ), Oxidation (M), and Carbamidomethylation (N-term) as variable modifications, and add Carbamidomethylation (C) as fixed modification.
  4. Choose Trypsin as digestion enzyme in the Digestion tab.
  5. Add the label free quantification option LFQ in the Label Free Quantification tab. If more than 10 files are to be processed, choose the Fast LFQ option to shorten the processing time. Add iBAQ option as a measure for protein quantification24.
  6. Ensure that all other group-specific parameters remain in factory settings.
  7. Proceed to the Global Parameters tab and add the FASTA file derived from uniprot.org in the Sequences tab. Modify the identifier rule accordingly and add the taxonomy ID, in this case, 9606 for homo sapiens.
  8. For protein quantification choose Unique and Razor peptides.
  9. Ensure that all other global parameters remain in factory settings.
  10. Click on Start and retrieve the proteingroups.txt output after MaxQuant analysis for further analysis in Perseus.

6. Statistical analysis using Perseus

  1. Load the proteingroups.txt file in Perseus, add the iBAQ values as main columns, and sort all other columns according to their type.
  2. Filter out decoys and contaminants by filtering rows based on the categorical column.
  3. Filter results based on valid values. In the present case, with only two samples included in the analysis, a minimum number of one valid value was chosen.
  4. Export the Perseus output in .txt format for further processing, for example, in Excel, and evaluate the results regarding the research question.

7. Validation of selected proteins

NOTE: Commonly used methods for validation of MS data are, for example, immunological staining or Western Blot. Due to the dark color and the autofluorescence of neuromelanin, immunological staining of proteins inside of neuromelanin granules either with horseradish peroxidase- or fluorophore-conjugated antibodies are not applicable. For Western Blot analysis, very large amounts of post-mortem tissue would be necessary. Therefore, selected proteins are validated by targeted mass spectrometry, and in the present case, parallel reaction monitoring (PRM)-experiments were set up.

  1. Select proteins for validation. Choose peptides of these proteins already detected in DDA experiments. Peptides should contain no missed cleavages or modifications to ensure a reliable quantification.
    NOTE: There can be several reasons for the validation of one specific protein, for example, differential abundances in the investigated conditions. For the representative results, cytoplasmic dynein 1 heavy chain 1 has been selected, which was found to be equivalently abundant in NMG and SN samples and could therefore be used as a reference to ensure equal sample loading.
  2. Use the selected peptides to set up the first version of a PRM-method using the HPLC software. Keep all chromatography and global parameters settings from the DDA method.
  3. Add MS OT and tMS2 OT HCD as scan types. Ensure that the settings for MS OT are the same as for the DDA method. Detailed settings for the PRM method can be found in Supplementary Table 1.
  4. For tMS2 OT HCD, add selected peptides as an inclusion list. Therefore, add the amino acid sequence and the m/z value observed in the DDA measurements. For the first PRM experiment, do not add retention time windows or set t start to 0 and t stop to 120 (for a 120 min gradient).
  5. Evaluate the PRM method after the measurement using suitable software, for example, Skyline, and obtain the retention time of the peptides added to the inclusion list. For included peptides, check that comparable peaks are observable for at least three precursor ions in MS1 scans and five fragment ions in MS2 scans with low mass error (±5 ppm).
  6. Refine the PRM method, for example, by increasing the resolution for the tMS2 OT HCD scan and adding retention time windows to the inclusion list.
    NOTE: Retention time windows of 3 min were found to be well-suited in present experiments (observed retention time in first PRM experiment ± 1.5 min).
  7. With the refined PRM-method, perform quantification of peptides and proteins of interest based on the peak area both on MS1 and MS2 levels with suitable software.

Representative Results

The specific isolation of NMGs and SN tissue is the most important step for the successful application of this protocol. Using the Field of View Analysis function in the vendor-provided software of the LMD, NMGs can be automatically selected in a color-dependent manner. Therefore, tissue areas containing NMGs (Figure 2A) have to be identified and a Field of View Analysis with adjusted color thresholds has to be performed, resulting in the labeling of NMGs (Figure 2B). After filtering of objects covering an area below 100 µm², only NMGs should remain labeled for isolation (Figure 2C). Precise isolation of the labeled NMGs is achieved after laser settings were adjusted (Figure 2D). After the isolation of NMGs (Figure 2E), SN tissue can be selected with 50-fold magnification (Figure 2F) and isolated (Figure 2G) for comparison of the proteomic profile. For SN tissue, isolated objects can be visualized using the Cap Check function (Figure 2H). For both sample types, NMG and SN, isolation of 500,000 µm2 of brain tissue was found to be sufficient for this protocol, enabling a minimum of three MS runs per sample.

A representative example of a 120 min DDA experiment is shown in Figure 3 (as the main column is washed in the last 15 min of the measurement, the chromatogram is cropped just before 105 min). The applied method should allow a sample elution over the complete gradient, creating sharp and concise peaks and the intensity of the Total Ion current (TIC) should be comparable across all samples.

Application of the presented protocol on one sample of 500,000 µm² of NMG and one sample of 1,000,000 µm² SN tissue with adjusted volumes for MS samples (5 µL for NMG and 2.5 µL for SN) to ensure identical peptide load, resulted in the identification of 1,898 protein groups (PGs) in the NMG sample and 1,565 PGs in the SN sample. Further comparison revealed 1,384 PGs to be identified in both samples, while 514 PGs were exclusively identified in NMG and 181 PGs in SN tissue (Figure 4). In total, 2,079 PGs were identified in this representative experiment. Comparison with a reference dataset from a former study22 showed that 87.6% of the PGs reported in that study could also be identified by the present revised and automated protocol, proving its applicability. Furthermore, the number of identified PGs could be improved by 1,143.

As minimal sample amounts do not allow the application of classic validation methods such as Western Blots, validation of proteins of interest can be achieved by targeted mass spectrometric approaches, e.g., PRM. Representative results for the peptide ESPEVLLTLDILK of the protein cytoplasmic dynein 1 heavy chain 1 are shown in Figure 5. The iBAQ value of this protein was found to be slightly higher in NMGs compared to SN in the DDA measurements, which could be verified by PRM-experiments based on the peak area on MS1- (Figure 5A,B,E) and MS2-level (Figure 5C,D,F).

Figure 1
Figure 1: Workflow for the proteomic characterization of neuromelanin granules (NMGs) and surrounding tissue (SN). NMG and SN samples were isolated from tissue slices via laser microdissection (LMD). Proteins were isolated and tryptic in-solution digestion was performed. The resulting peptides were analyzed via LC-MS/MS measurements in data-dependent acquisition (DDA) mode. Data analysis was performed using MaxQuant and Perseus software. Validation of selected proteins was carried out with parallel reaction monitoring (PRM) experiments. PRM-data was analyzed using Skyline software. Please click here to view a larger version of this figure.

Figure 2
Figure 2: Selection and LMD-based isolation of NMG and SN samples. At first, an area containing NMGs, visible without further staining at 400-fold magnification, is placed under the microscope (A). After performing a Field of View Analysis, NMGs and other dark areas are selected (B). Only NMGs remain selected after filtering (C) and are isolated after laser settings are adjusted (D). After all NMGs are isolated (E), SN tissue is selected with 50-fold magnification (F) and isolated (G). As objects isolated for SN samples are quite big, they can be observed in the sample collection cap using the Cap Check function (H). Please click here to view a larger version of this figure.

Figure 3
Figure 3: Total Ion Current (TIC) of a 120 min DDA measurement. The chromatogram shows the relative abundance of the ions corresponding to the eluting peptides over the retention time range from 0 to ~105 min. As the main column is washed between 105th and 120th min, the chromatogram is cropped at the 105th min. The intensity of the highest peak is 2.86 x 108. Numbers above peaks indicate the retention time and the most abundant ion of that specific peak (BP=base peak). Please click here to view a larger version of this figure.

Figure 4
Figure 4: Venn Diagram showing the correspondence of protein groups (PGs) identified in NMGs and SN tissue. In total, 1,898 PGs were identified in NMGs and 1,565 PGs in SN tissue, of which 1,384 PGs were identified in both tissue areas. 514 PGs were exclusively identified in NMG tissue, while 181 PGs were exclusively identified in SN tissue. The diagram was created using the online tool Venny25. Please click here to view a larger version of this figure.

Figure 5
Figure 5: Results of PRM-experiments for the peptide ESPEVLLTLDILK (cytoplasmic dynein 1 heavy chain 1, ++). Chromatograms on MS1- (A,B) and MS2-level (C,D), as well as peak areas on MS1- (E) and MS2-level (F), are shown for an exemplary sample of NMGs and SN tissue. Different colors are used to denote different precursors (on MS1-level) or product ions (on MS2-level). Chromatograms are displayed after Savitzky-Golay Smoothing was performed. Intensities and peak areas were comparable on MS1- (A,B,E) and MS2-level (C,D,F). Please click here to view a larger version of this figure.

Supplementary Table 1: Parameters of the mass spectrometry experiments. Please click here to download this Table.

Supplementary Table 2: Parameters of the MaxQuant analysis. Please click here to download this Table.

Discussion

LMD is a widely applicable technique for the isolation of specific tissue areas, single cells, or subcellular structures. In the revised and automated protocol presented here, this technique is applied for the specific isolation of neuromelanin granules (NMGs) and NMG-surrounding tissue (SN). Until now, two different approaches for the isolation of NMGs out of human post-mortem brain tissue were published and widely used:

a) A discontinuous sucrose gradient consuming 1 g of substantia nigra tissue20. As human post-mortem substantia nigra tissue is rare and of high interest for several research questions, it is unfortunately quite challenging to set up a large cohort study if high amounts of tissue are required per patient. Therefore, this approach was further improved reducing the required tissue amount to 0.15 g for sufficient isolation of NMGs26. However, still, at least one-half of a complete substantia nigra pars compacta was required.

b) The excision of NMGs using LMD. In 2016, Plum et al established a new protocol based on the precise excision of NMGs via LMD. With this protocol, the required sample amount could be reduced to ten 10 µm tissue sections, resulting in an impressive reduction of the required tissue sample from 150 mg to 16.6 mg22.

The optimized and automated LMD-based protocol presented here requires even lower sample amounts as thinner (5 µm compared to 10 µm) and fewer tissue sections (maximum of 7 compared to 8) had to be used and requires less time for sample generation (4 h per sample compared to 1-2 days) through the use of automatized NMG detection. Thus, the required sample collection time was shortened massively and the number of identified PGs could be drastically enhanced by applying an optimized LC-MS method and state-of-the-art instrumentation. This protocol can easily be adapted to other research questions and tissues.

For the adaptation of the presented protocol concerning user-defined research questions, the following aspects are highlighted based on experience:

a) Isolation of comparable sample amounts: As the expected peptide yield of this protocol is rather low compared to, for instance, cell culture or tissue lysates, determination of peptide concentration may not be possible. Thus, it is crucial that equal amounts of tissue are isolated via LMD, which can be estimated based on the tissue area of the selected objects. In the current setup, tissue areas of 500,000 µm² are sufficient for the generation of peptides for at least three MS measurements.

b) Trypsin-digestion: The duration of digestion and the trypsin concentration should be comparable across samples.

c) Adaption of parameters for different tissues: Depending on the tissue to analyze, the collected tissue amount needs to be adjusted thereby making it necessary to adjust the amount of added trypsin as well. The trypsin to protein ratio should not be lower than 1:40.

d) Limitation of the LMD process: For the LMD-based isolation of objects of interest, there are limitations when it comes to the size of selected objects and the thickness of slices. Due to tissue loss during the laser-based cutting of the tissue, objects smaller than 100 µm² were considered too small for isolation.

e) Adaption of LC and MS parameters: Depending on the LC and MS systems used, the amount of isolated tissue has to be increased (e.g., when operating with a microflow system) and MS parameters have to be adapted (e.g., when working with an ion-trap-based detector system).

Divulgaciones

The authors have nothing to disclose.

Acknowledgements

This work was supported by de.NBI, a project of the German Federal Ministry of Education and Research (BMBF) (grant number FKZ 031 A 534A) and P.U.R.E. (Protein Research Unit Ruhr within Europe) and Center for Protein Diagnostics (ProDi) grants, both from the Ministry of Innovation, Science and Research of North-Rhine Westphalia, Germany.

Materials

1,4-dithiothreitol AppliChem A1101
Acetonitrile Merck 1.00029.2500
Ammonium bicarbonate Sigma-Aldrich A6141
Formic acid Sigma-Aldrich 56302
Iodoacetamide AppliChem A1666,0100
Micro Tube 500 Carl Zeiss 415190-9221-000
Orbitrap Fusion Lumos Tribrid mass spectrometer Thermo Fisher Scientific IQLAAEGAAPFADBMBHQ
PALM MicroBeam Zeiss 494800-0014-000
PEN Membrane slide Carl Zeiss 415190-9041-000
substantia nigra pars compacta tissue slices Navarrabiomed Biobank (Pamplona, Spain)
Trifluoroacetic acid Merck 91707
Trypsin sequencing grade Serva 37283.01
Ultimate 3000 RSLC nano LC system Thermo Fisher Scientific ULTIM3000RSLCNANO
Name of Software Weblink/Company Version
FreeStyle Thermo Fisher Scientific 1.6
MaxQuant https://www.maxquant.org/ 1.6.17.0
PALMRobo Zeiss 4.6 pro
Perseus https://www.maxquant.org/perseus/ 1.6.15.0
Skyline https://skyline.ms/project/home/software/Skyline/begin.view 20.2.0.343
XCalibur Thermo Fisher Scientific 4.3

Referencias

  1. Li, C., et al. DNA profiling of spermatozoa by laser capture microdissection and low volume-PCR. PloS One. 6 (8), 22316 (2011).
  2. Butler, A. E., et al. Recovery of high-quality RNA from laser capture microdissected human and rodent pancreas. Journal of Histotechnology. 39 (2), 59-65 (2016).
  3. Eggers, B., et al. Advanced fiber type-specific protein profiles derived from adult murine skeletal muscle. Proteomes. 9 (2), 28 (2021).
  4. Kley, R. A., et al. A combined laser microdissection and mass spectrometry approach reveals new disease relevant proteins accumulating in aggregates of filaminopathy patients. Molecular & Cellular Proteomics: MCP. 12 (1), 215-227 (2013).
  5. Güttsches, A. -. K., et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Annals of Neurology. 81 (2), 227-239 (2017).
  6. Bogerts, B. A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. The Journal of Comparative Neurology. 197 (1), 63-80 (1981).
  7. Engelen, M., et al. Neuromelanins of human brain have soluble and insoluble components with dolichols attached to the melanic structure. PloS One. 7 (11), 48490 (2012).
  8. Duffy, P. E., Tennyson, V. M. Phase and electron microscopic observations of lewy bodies and melanin granules in the substantia nigra and locus caeruleus in parkinsonʼs disease. Journal of Neuropathology and Experimental Neurology. 24 (3), 398-414 (1965).
  9. Zecca, L., et al. Interaction of human substantia nigra neuromelanin with lipids and peptides. Journal of Neurochemistry. 74 (4), 1758-1765 (2000).
  10. Fenichel, G. M., Bazelon, M. Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology. 18 (8), 817-820 (1968).
  11. Halliday, G. M., et al. Evidence for specific phases in the development of human neuromelanin. Journal of Neural Transmission. 113 (6), 721-728 (2006).
  12. Zucca, F. A., et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Progress in Neurobiology. 155, 96-119 (2017).
  13. Carballo-Carbajal, I., et al. Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis. Nature Communications. 10 (1), 973 (2019).
  14. Zecca, L., Zucca, F. A., Wilms, H., Sulzer, D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends in Neurosciences. 26 (11), 578-580 (2003).
  15. Paris, I., Lozano, J., Perez-Pastene, C., Muñoz, P., Segura-Aguilar, J. Molecular and neurochemical mechanisms in PD pathogenesis. Neurotoxicity Research. 16 (3), 271-279 (2009).
  16. Zecca, L., et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. Journal of Neurochemistry. 106 (4), 1866-1875 (2008).
  17. Zarȩba, M., Bober, A., Korytowski, W., Zecca, L., Sarna, T. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 1271 (2-3), 343-348 (1995).
  18. Karlsson, O., Lindquist, N. G. Melanin affinity and its possible role in neurodegeneration. Journal of neural transmission. 120 (12), 1623-1630 (2013).
  19. Marsden, C. D. Pigmentation in the nucleus substantiae nigrae of mammals. Journal of Anatomy. 95, 256-261 (1961).
  20. Tribl, F., et al. 34;Subcellular proteomics" of neuromelanin granules isolated from the human brain. Molecular & Cellular Proteomics: MCP. 4 (7), 945-957 (2005).
  21. Zucca, F. A., et al. Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease. NPJ Parkinson’s Disease. 4, 17 (2018).
  22. Plum, S., et al. Proteomic characterization of neuromelanin granules isolated from human substantia nigra by laser-microdissection. Scientific Reports. 6, 37139 (2016).
  23. Tyanova, S., Temu, T., Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nature Protocols. 11 (12), 2301-2319 (2016).
  24. Krey, J. F., et al. Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Scientific Data. 5, 180128 (2018).
  25. . Venny: An interactive tool for comparing lists with Venn’s diagrams Available from: https://bioinfogp.cnb.csic.es/tools/venny/index.html (2007)
  26. Plum, S., et al. Combined enrichment of neuromelanin granules and synaptosomes from human substantia nigra pars compacta tissue for proteomic analysis. Journal of Proteomics. 94, 202-206 (2013).

Play Video

Citar este artículo
Wulf, M., Barkovits-Boeddinghaus, K., Sommer, P., Schork, K., Eisenacher, M., Riederer, P., Gerlach, M., Kösters, S., Eggers, B., Marcus, K. Laser Microdissection-Based Protocol for the LC-MS/MS Analysis of the Proteomic Profile of Neuromelanin Granules. J. Vis. Exp. (178), e63289, doi:10.3791/63289 (2021).

View Video